SOURCE: CLX Investment Company, Inc.

June 13, 2006 09:20 ET

CLX Investment Company Announces New Shipment of Zonda Chlamydia Test to the United Kingdom

TEMECULA, CA -- (MARKET WIRE) -- June 13, 2006 -- CLX Investment Company, Inc. (OTCBB: CLXN) today announced that portfolio investment Zonda Inc., which specializes in diagnostic tests that serve the medical, bacterial food safety, cosmetic, beverage, pharmaceutical, veterinary, and environmental sanitation testing markets, has recently completed a new shipment of its HandiLab-C test for chlamydia to the United Kingdom. The shipment of HandiLab-C tests was sent to Zonda's distributor for pharmacies and other retail locations across the United Kingdom.

"As we continue to open new markets for HandiLab-C test and other medical diagnostic tests in the Zonda, Inc. product line, we are pleased to see continued demand in established markets," stated Robert McCoy, chairman and chief executive officer of CLX Investment Company. "The HandiLab-C has been sold in the United Kingdom since November of 2004, and while CLX will not announce every shipment of Zonda's products, we felt that it was important to make our shareholders aware of the numerous European markets in which the HandiLab-C is currently being sold."

"In addition to European markets, we are working closely with Zonda, Inc. to support the company's efforts to gain regulatory approvals worldwide, and we expect progress in several of large global markets in the near term," added Mr. McCoy.

Zonda's HandiLab-C test, the only over-the-counter test (self testing) for chlamydia that carries the CE mark, which signifies that the product complies with the relevant health, safety, environmental protection requirements in Europe and can therefore be legally placed on the market, is currently distributed to pharmacies in a growing number of European markets.

To sign up to receive information by email directly from CLX Investment Company when new press releases, investor newsletters, SEC filings, or other information is disclosed, please visit http://www.clxinvestments.com/email.asp.

About Zonda, Inc.

Zonda, Inc. (www.zondaincusa.com), in which CLX holds a 31% equity interest, specializes in diagnostic tests that serve the medical, bacterial food safety, cosmetic, beverage, pharmaceutical, veterinary, and environmental sanitation testing markets. Zonda's product line includes innovative, rapid, self-contained diagnostic devices for the detection of chlamydia, gonorrhea, yeast (Candida albicans) and Group A Strep, tests that detect bacterial and other potential harmful micro-organisms on surfaces, and confirmation tests for a wide variety of bacteria. The HandiLab-C test for chlamydia carries a CE mark for both professional point-of-care and over-the-counter use. The gonorrhea, yeast and Group A Strep tests carry CE marks for professional point-of-care use, and Zonda is seeking similar approvals for over-the-counter sales of these products. Each of the Zonda infectious disease tests are marketed as superior to their competition due to their comparable accuracy (compared directly to PCR or DNA testing), ease of use, compact design, long shelf life, rapid results, and cost effectiveness.

About CLX Investment Company

CLX Investment Company (www.clxinvestments.com) holds a 31% equity interest in Zonda, Inc. (www.zondaincusa.com), a privately held company that specializes in test products that serve the medical, bacterial food safety, cosmetic, beverage, pharmaceutical, veterinary, and environmental sanitation testing markets. Also in the CLX investment portfolio is a 49% interest in eStrategy Solutions, Inc. (www.estrategysolutions.com), a Texas-based e-learning provider that has developed online training solutions for government entities and other professional organizations. CLX has invested, and holds a common stock position, in ActionView International, Inc. (www.actionviewinternational.com), a publicly traded global manufacturer and marketer of "smart" scrolling advertising billboards.

CLX has elected to be regulated as a Business Development Company pursuant to Section 54 of the Investment Company Act of 1940, and is pursuing a business plan wherein the Company seeks to make investment in developing companies with the goal of providing return for its shareholders.

All statements included in this release, including statements regarding potential future plans and objectives of CLX Investments are forward-looking statements. Such statements are necessarily subject to risks and uncertainties, some of which are significant in scope and nature beyond CLX Investments' control. There can be no assurance that such statements will prove accurate. Actual results and future events could differ materially from those anticipated in such statements depending on many factors. Historical results are not necessarily indicative of future performance.

Contact Information

  • Contact:
    Gemini Financial Communications
    A. Beyer
    951-587-8072
    Email Contact